TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The antifungal, immunosuppressive compound rapamycin arrests the cell cycle in G1 in both yeast cells and T-lymphocytes. Previous genetic studies in yeast identified mutations in three genes, FPR1 (FKBP12), TOR1, and TOR2, which confer rapamycin resistance, and genetic findings implicated the TOR proteins as direct targets of FKBP12-rapamycin. Consistent with this model, we find that modulating TOR1 and TOR2 expression alters rapamycin sensitivity. We describe several TOR2 mutations that confer rapamycin resistance. These mutations prevent FKBP12-rapamycin binding to TOR2, as assayed with the two-hybrid system. We find that TOR1 and the mammalian TOR homologue (mTOR) also bind FKBP12-rapamycin, and mutations corresponding to those in TOR2 similarly block FKBP12-rapamycin binding. We demonstrate that FKBP12 prolyl isomerase activity is not required for FKBP12-rapamycin binding to TOR and that a composite protein-drug surface contacts the TOR proteins. These studies confirm that the TOR proteins are direct targets of FKBP12-rapamycin, reveal that drug-resistant mutations prevent this association, and define structural features of these complexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
Liu, J., Farmer, J. D., Lane, W. S., Friedman, J., Weissman, I., & Schreiber, S. L. (1991) · Cell · doi:10.1016/0092-8674(91)90124-h · Cited by 4,116
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Chen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556
RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
Chiu, M. I., Katz, H., & Berlin, V (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12574 · Cited by 481
Kato, R., & Ogawa, H. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.15.3104 · Cited by 218
Albers, M. W., Williams, R. T., Brown, E. J., Tanaka, A., Hall, F. L., & Schreiber, S. L. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41602-x · Cited by 145
Wiederrecht, G., Hung, S., Chan, H. K., Marcy, A., Martin, M., Calaycay, J., Boulton, D., Sigal, N., Kincaid, R. L., & Siekierka, J. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36676-1 · Cited by 115
Cited by
PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor)
Marx, S. O., Reiken, S., Hisamatsu, Y., Jayaraman, T., Burkhoff, D., Rosemblit, N., & Marks, A. R. (2000) · Cell · doi:10.1016/s0092-8674(00)80847-8 · Cited by 1,978
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886
“Lysates Kunz et al., 1993; Lorenz and Heitman, 1995; Stan et al., were subjected to IgG pull-down (FPR1-TAP pull-down) or immuno1994).”
BackgroundRegulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in Yeast
Noda, T., & Ohsumi, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.3963 · Cited by 1,309
MAP Kinase Pathways in the Yeast Saccharomyces cerevisiae
Gustin, M. C., Albertyn, J., Alexander, M., & Davenport, K. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.4.1264-1300.1998 · Cited by 953
Structure of the FKBP12-Rapamycin Complex Interacting with Binding Domain of Human FRAP
Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996) · Science · doi:10.1126/science.273.5272.239 · Cited by 929
Target of Rapamycin (TOR) in Nutrient Signaling and Growth Control
Loewith, R., & Hall, M. N. (2011) · Genetics · doi:10.1534/genetics.111.133363 · Cited by 910
Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., Flask, C. A., Novick, A. C., Goldfarb, D. A., Kramer-Zucker, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509694103 · Cited by 808
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Clinical Pharmacokinetics of Everolimus
Kirchner, G. I., Meier-Wiedenbach, I., & Manns, M. P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443020-00002 · Cited by 508
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Rodrik-Outmezguine, V. S., Okaniwa, M., Yao, Z., Novotny, C. J., McWhirter, C., Banaji, A., Won, H., Wong, W., Berger, M., de Stanchina, E., et al. (2016) · Nature · doi:10.1038/nature17963 · Cited by 479
Rapamycin Protects against Neuron Death in In Vitro and In Vivo Models of Parkinson's Disease
Malagelada, C., Jin, Z. H., Jackson-Lewis, V., Przedborski, S., & Greene, L. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3944-09.2010 · Cited by 462
eIF4E – from translation to transformation
Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L. W., & Sonenberg, N. (2004) · Oncogene · doi:10.1038/sj.onc.1207549 · Cited by 449
Autophagy in neurodegenerative diseases: pathogenesis and therapy
Guo, F., Liu, X., Cai, H., & Le, W. (2018) · Brain Pathology · doi:10.1111/bpa.12545 · Cited by 444
Husain, S., Wagener, M. M., & Singh, N. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0703.010302 · Cited by 405
Elucidating TOR Signaling and Rapamycin Action: Lessons from Saccharomyces cerevisiae
Crespo, J. L., & Hall, M. N. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.4.579-591.2002 · Cited by 365
The TOR Kinases Link Nutrient Sensing to Cell Growth
Rohde, J., Heitman, J., & Cardenas, M. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r000034200 · Cited by 351
Self-citationJiang, Y., & Broach, J. R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.10.2782 · Cited by 338
PI3 Kinase Regulation of Skeletal Muscle Hypertrophy and Atrophy
Glass, D. J. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_78 · Cited by 333
Autophagy and neurodegeneration
Frake, R. A., Ricketts, T., Menzies, F. M., & Rubinsztein, D. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73944 · Cited by 332
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Wagle, N., Grabiner, B. C., Van Allen, E. M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., Gray, N., Barletta, J. A., Guo, Y., Swanson, S. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403352 · Cited by 321
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.659 · Cited by 314
The role of skeletal muscle mTOR in the regulation of mechanical load‐induced growth
Goodman, C. A., Frey, J. W., Mabrey, D. M., Jacobs, B. L., Lincoln, H. C., You, J., & Hornberger, T. A. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.218255 · Cited by 297
A Review of Phenotypes in Saccharomyces cerevisiae
Hampsey, M. (1997) · Yeast · doi:10.1002/(sici)1097-0061(19970930)13:12<1099::aid-yea177>3.0.co;2-7 · Cited by 276
Current treatment strategies for inhibiting mTOR in cancer
Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 275
Lezon, T. R., Banavar, J. R., Cieplak, M., Maritan, A., & Fedoroff, N. V. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609152103 · Cited by 269
Balancing mTOR Signaling and Autophagy in the Treatment of Parkinson’s Disease
Zhu, Z., Yang, C., Iyaswamy, A., Krishnamoorthi, S., Sreenivasmurthy, S. G., Liu, J., Wang, Z., Tong, B. C.-K., Song, J., Lu, J., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030728 · Cited by 263
Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle
Hornberger, T. A. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.05.007 · Cited by 170
“Mutating the 2035S residue in the FRB domain to 2035T inhibits the interaction of mTOR with the FKBP12-rapamycin complex and renders this mutant of mTOR (RR-mTOR) rapamycin-resistant (Lorenz and Heitman, 1995, Brown et al., 1995).”
BackgroundCruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., & Heitman, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3162-3170.2001 · Cited by 159
Self-citationSignal-transduction cascades as targets for therapeutic intervention by natural products
Cardenas, M. E., Sanfridson, A., Cutler, N. S., & Heitman, J. (1998) · Trends in Biotechnology · doi:10.1016/s0167-7799(98)01239-6 · Cited by 101
Self-citationKim, J. H., Lee, C., Lee, M., Wang, H., Kim, K., Park, S. J., Yoon, I., Jang, J., Zhao, H., Kim, H. K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00785-0 · Cited by 88
Multi-timescale dynamics study of FKBP12 along the rapamycin–mTOR binding coordinate
Sapienza, P. J., Mauldin, R. V., & Lee, A. L. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.10.037 · Cited by 32
Chemical Screening Pipeline for Identification of Specific Plant Autophagy Modulators
Dauphinee, A. N., Cardoso, C., Dalman, K., Ohlsson, J. A., Fick, S. B., Robert, S., Hicks, G. R., Bozhkov, P. V., & Minina, E. A. (2019) · Plant Physiology · doi:10.1104/pp.19.00647 · Cited by 30
Metadata
- Authors
- Lorenz, M. C., & Heitman, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-11
- Volume
- 270
- Issue
- 46
- Pages
- 27531-27537
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1991691392
- Cited by
- 238
- References
- 9
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.